<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.27711.006</object-id><label>Table 1.</label><caption><p>Properties of synthesized [Lys(ClAc)]-peptide derivatives. X represents substitution of the two Met residues in position 21 and 38 to Norleucine. dF indicates the N-terminal D-Phe<sup>12</sup> of the CRF(12-41) analogues. EC<sub>50</sub> values of agonists were derived from the function of cAMP level in transiently transfected HEK293 cells and are shown as mean &#177; s.e.m. The percentage of receptor activation at 100 nM concentration of antagonists are normalized to either Ucn1 or CRF and are shown as mean &#177; s.e.m [%]. All values are obtained from at least three independent experiments, each performed in triplicate. Purity is given as the area% of the peak corresponding to the peptide&#160;with respect to total area in analytic HPLC (UV detection, 220 nm). Molecular weights and m/z values from MALDI-Tof mass spectrometry are monoisotopic.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.27711.006">http://dx.doi.org/10.7554/eLife.27711.006</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Peptides</th><th valign="top">Receptor activation</th><th colspan="3" valign="top">Analytic data</th></tr><tr><th valign="top"/><th valign="top"/><th>Purity (Area%)</th><th>M calculated</th><th>[M+H]<sup>+</sup> found</th></tr><tr><th valign="top">Agonists</th><th valign="top">EC<sub>50</sub> [nM]</th><th valign="top"/><th valign="top"/><th valign="top"/></tr></thead><tbody><tr><td valign="top">Ucn1</td><td valign="top">0.16&#160;&#177;&#160;0.11</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">CRF</td><td valign="top">0.11&#160;&#177;&#160;0.13</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">[Lys(ClAc)<sup>12</sup>]-<sup>X</sup>CRF</td><td>3.39&#160;&#177;&#160;0.02</td><td valign="top">&gt;96%</td><td valign="bottom">4775.57</td><td valign="top">4776.52</td></tr><tr><td valign="top">[Lys(ClAc)<sup>13</sup>]- <sup>X</sup>CRF</td><td>0.03&#160;&#177;&#160;0.16</td><td valign="top">&gt;96%</td><td valign="bottom">4785.58</td><td valign="top">4786.55</td></tr><tr><td valign="top">[Lys(ClAc)<sup>14</sup>]- <sup>X</sup>CRF</td><td>0.79&#160;&#177;&#160;0.07</td><td valign="top">&gt;95%</td><td valign="bottom">4809.56</td><td valign="top">4810.52</td></tr><tr><td valign="top">[Lys(ClAc)<sup>15</sup>]- <sup>X</sup>CRF</td><td>0.08&#160;&#177;&#160;0.22</td><td valign="top">&gt;95%</td><td valign="bottom">4809.56</td><td valign="top">4810.55</td></tr><tr><td valign="top">[Lys(ClAc)<sup>16</sup>]- <sup>X</sup>CRF</td><td>0.20&#160;&#177;&#160;0.03</td><td valign="top">&gt;95%</td><td valign="bottom">4766.54</td><td valign="top">4767.58</td></tr><tr><td valign="top">[Lys(ClAc)<sup>17</sup>]- <sup>X</sup>CRF</td><td>0.08&#160;&#177;&#160;0.26</td><td valign="top">&gt;95%</td><td valign="bottom">4793.60</td><td valign="top">4794.64</td></tr><tr><td valign="top">[Lys(ClAc)<sup>18</sup>]- <sup>X</sup>CRF</td><td>0.03&#160;&#177;&#160;0.16</td><td valign="top">&gt;97%</td><td valign="top">4823.57</td><td valign="top">4824.30</td></tr><tr><td valign="top">[Lys(ClAc)<sup>31</sup>]- <sup>X</sup>CRF</td><td>0.06&#160;&#177;&#160;0.11</td><td valign="top">&gt;98%</td><td valign="top">4851.61</td><td valign="top">4852.88</td></tr><tr><td valign="top">[Lys(ClAc)<sup>33</sup>]- <sup>X</sup>CRF</td><td>0.04&#160;&#177;&#160;0.16</td><td valign="top">&gt;95%</td><td valign="top">4835.61</td><td valign="top">4836.90</td></tr><tr><td valign="bottom"><bold>Antagonists</bold></td><td><bold>Receptor activation at 100 nM [%]</bold></td><td/><td/><td/></tr><tr><td valign="top">Ucn1(8-40)</td><td>8.20&#160;&#177;&#160;2.76</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">CRF(9-41)</td><td>4.03&#160;&#177;&#160;1.27</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top"><sup>dFX</sup>CRF(12-41)</td><td>0.53&#160;&#177;&#160;0.47</td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;[ClAc<sup>0</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>0.62&#160;&#177;&#160;0.57</td><td valign="top">&gt;95%</td><td valign="top">3612.97</td><td valign="top">3613.91</td></tr><tr><td valign="top">[Lys(ClAc)<sup>13</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>2.41&#160;&#177;&#160;0.71</td><td valign="top">&gt;95%</td><td valign="top">3604.00</td><td valign="top">3605.09</td></tr><tr><td valign="top">[Lys(ClAc)<sup>14</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>1.49&#160;&#177;&#160;0.98</td><td valign="top">&gt;95%</td><td valign="top">3627.98</td><td valign="top">3628.99</td></tr><tr><td valign="top">[Lys(ClAc)<sup>15</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>0.39&#160;&#177;&#160;0.27</td><td valign="top">&gt;97%</td><td valign="top">3627.98</td><td valign="top">3628.97</td></tr><tr><td valign="top">[Lys(ClAc)<sup>16</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>1.06&#160;&#177;&#160;0.81</td><td valign="top">&gt;95%</td><td valign="top">3584.96</td><td valign="top">3585.99</td></tr><tr><td valign="top">[Lys(ClAc)<sup>17</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>0.31&#160;&#177;&#160;0.10</td><td valign="top">&gt;95%</td><td valign="top">3612.02</td><td valign="top">3613.08</td></tr><tr><td valign="top">[Lys(ClAc)<sup>18</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>0.59&#160;&#177;&#160;0.14</td><td valign="top">&gt;95%</td><td valign="top">3641.99</td><td valign="top">3643.07</td></tr><tr><td valign="top">[Lys(ClAc)<sup>31</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>0.52&#160;&#177;&#160;0.15</td><td valign="top">&gt;95%</td><td valign="top">3670.02</td><td valign="top">3671.03</td></tr><tr><td valign="top">[Lys(ClAc)<sup>33</sup>]- <sup>dFX</sup>CRF(12-41)</td><td>1.85&#160;&#177;&#160;0.19</td><td valign="top">&gt;99%</td><td valign="top">3654.03</td><td valign="top">3655.13</td></tr></tbody></table></table-wrap>